All of the following drugs are FDA approved for the treatment of minimally classic subfoveal CNV in patients with neovascular AMD with evidence of recent disease progression (loss of vision, growth of CNV on FA, new macular hemorrhage) except for which one?

Posted: April 17, 2008
All of the following drugs are FDA approved for the treatment of minimally classic subfoveal CNV in patients with neovascular AMD with evidence of recent disease progression (loss of vision, growth of CNV on FA, new macular hemorrhage) except for which one?
  1. a) Pegaptanib sodium (Macugen)
  2. b) Verteporfin (Visudyne PDT)
  3. c) Ranibizumab (Lucentis)
  4. d) None of the above
  5. e) All of the above

Correct Answer: Verteporfin (Visudyne PDT)

Although typically reimbursed for the described diagnosis, verteporfin is FDA approved in fact only for the treatment of subfoveal CNV predominantly classic due to neovascular AMD.

Recent Quick Quizzes

Page